Chidamide is subtype-selective histone deacetylase (HDAC) inhibitor that showed promising result in clinical trials to improve prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients. The gene discussed is HDAC9; the disease is angioimmunoblastic T-cell lymphoma.